Stephen Anthony Stamp - 18 Mar 2026 Form 3 Insider Report for Biodexa Pharmaceuticals Plc (BDRX)

Role
Chief Executive Officer, Director
Signature
/s/ Fiona Mary Powell, Attorney-in-Fact
Issuer symbol
BDRX
Transactions as of
18 Mar 2026
Net transactions value
$0
Form type
3
Filing time
18 Mar 2026, 09:30:18 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Stamp Stephen Anthony Chief Executive Officer, Director C/O BIODEXA PHARMACEUTICALS PLC, 1 CASPIAN POINT, CASPIAN WAY, CARDIFF, UNITED KINGDOM /s/ Fiona Mary Powell, Attorney-in-Fact 18 Mar 2026 0002111962

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BDRX Stock Option (right to buy) 18 Mar 2026 American Depositary Shares 859 $327.50 Direct F1, F2, F4
holding BDRX Stock Option (right to buy) 18 Mar 2026 Ordinary Shares 1,500 $28.05 Direct F3, F5
holding BDRX Stock Option (right to buy) 18 Mar 2026 Ordinary Shares 25,000 $7.41 Direct F3, F6
holding BDRX Stock Option (right to buy) 18 Mar 2026 Ordinary Shares 15,000 $5.40 Direct F3, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying this option vest over a four-year period with (i) 25% vesting on the one-year anniversary of grant, and (ii) 6.25% vesting every three months thereafter, subject to the Reporting Person's continued service through the applicable vesting date.
F2 Each American Depositary Share represents 100,000 ordinary shares, nominal value PS0.000001 per share, of the Issuer.
F3 The shares underlying this option are 100% vested and can be exercised immediately.
F4 The exercise price for this option is denominated in British pounds sterling at a price of GBP 259.324 per American Depositary Share. The exercise price reported herein was converted into British pound sterling to United States dollars at a conversion rate of GBP 1.00 to USD 1.2629. The exercise price is the actual British pound sterling amount regardless of the exchange rate on the date of exercise.
F5 The exercise price for this option is denominated in British pounds sterling at a price of GBP 21.00 per Ordinary Share. The exercise price reported herein was converted into British pound sterling to United States dollars at a conversion rate of GBP 1.00 to USD 1.3355 as of March 17, 2026. The exercise price is the actual British pound sterling amount regardless of the exchange rate on the date of exercise.
F6 The exercise price for this option is denominated in British pounds sterling at a price of GBP 5.55 per Ordinary Share. The exercise price reported herein was converted into British pound sterling to United States dollars at a conversion rate of GBP 1.00 to USD 1.3355 as of March 17, 2026. The exercise price is the actual British pound sterling amount regardless of the exchange rate on the date of exercise.
F7 The exercise price for this option is denominated in British pounds sterling at a price of GBP 4.04 per Ordinary Share. The exercise price reported herein was converted into British pound sterling to United States dollars at a conversion rate of GBP 1.00 to USD 1.3355 as of March 17, 2026. The exercise price is the actual British pound sterling amount regardless of the exchange rate on the date of exercise.

Remarks:

Exhibit 24.1 -- Power of Attorney